Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 49
2021 56
2022 39
2023 38
2024 43
2025 44
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Results by year

Filters applied: . Clear all
The following term was ignored: (
Page 1
Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.
Khan F, Tritschler T, Marx CE, Lanting V, Rochwerg B, Tran A, Fernando SM, Lorenzetti DL, Wunsch H, Holodinsky J, Fiest K, Stelfox HT, Delluc A, Fergusson DA, Le Gal G, Wells PS, Wang TF, Sanfilippo K, van Es N, Schrag D, Connors JM, Carrier M. Khan F, et al. Eur Heart J. 2026 Apr 22;47(16):1917-1929. doi: 10.1093/eurheartj/ehaf453. Eur Heart J. 2026. PMID: 40579365 Review.
Conversely, recent surgery [aHR 0.56 (95% CI 0.40-0.76)] and breast cancer [0.43 (0.23-0.81)] had a high certainty of association with a decreased risk. ...
Conversely, recent surgery [aHR 0.56 (95% CI 0.40-0.76)] and breast cancer [0.43 (0.23-0.81)] had a high certainty of associat …
Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.
Pilgram L, Yang K, Beltran-Bless AA, Pond GR, Vandermeer L, Hilton J, Savard MF, LeBlanc A, Shepherd L, Chen B, Bartlett JM, Taylor KJ, Bayani J, Barker S, Spears M, van der Velde CJ, Meershoek-Klein Kranenbarg E, Dirix L, Mallon E, Hasenburg A, Markopoulos C, Juwara L, Dankar FK, Clemons M, El Emam K. Pilgram L, et al. J Med Internet Res. 2026 Apr 14;28:e88665. doi: 10.2196/88665. J Med Internet Res. 2026. PMID: 41980703 Free article.
BACKGROUND: Prognostic information is essential for decision-making in breast cancer management. In recent years, trials and clinical practice have emphasized genomic prognostication tools, despite clinicopathological methods being more affordable and accessible. .. …
BACKGROUND: Prognostic information is essential for decision-making in breast cancer management. In recent years, trials and c …
An ounce of "superscreener": A novel cancer screening program targeting unattached individuals.
Wilkinson AN, Volpini K, Naufer A, Miville A, Lalonde C, Kamikazi E, Hepworth-Junkin S. Wilkinson AN, et al. Can J Public Health. 2026 Mar 19. doi: 10.17269/s41997-026-01169-y. Online ahead of print. Can J Public Health. 2026. PMID: 41857457
High-risk referrals were significantly higher than provincial rates for colorectal (41.5% vs. 2.6%, p < 0.01) and breast cancer (27.3% vs. 1.1%, p < 0.01). Among participants, 195 (36.4%) were neverscreeners. ...

High-risk referrals were significantly higher than provincial rates for colorectal (41.5% vs. 2.6%, p < 0.01) and breast cancer

…
Correction to: A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy targeted therapy in HR + HER2-negative advanced breast cancer.
Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S. Doyle C, et al. Breast Cancer Res Treat. 2026 Mar 19;216(3):32. doi: 10.1007/s10549-026-07934-4. Breast Cancer Res Treat. 2026. PMID: 41854885 Free PMC article. No abstract available.
Composite pathway-guided Cox modeling for interpretable survival prediction in breast cancer.
Hefny MS. Hefny MS. J Biomed Inform. 2026 Mar 16;178:105021. doi: 10.1016/j.jbi.2026.105021. Online ahead of print. J Biomed Inform. 2026. PMID: 41850346 Free article.
Accurate survival prediction in breast cancer is essential for patient risk stratification and personalized treatment planning. ...Furthermore, the composite model highlights biologically plausible gene signatures and pathways associated with breast cancer …
Accurate survival prediction in breast cancer is essential for patient risk stratification and personalized treatment planning …
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.
Gambaro K, Rachedi K, Basik M, Batist G, Saad F, Hassan S, Mes-Masson AM, Boudreau D, Vincent F, St-Hilaire E, Mackay H, Abdelsalam M, Yip SM, Hanel R, Shokar S, Senhaji Mouhri Z, Badin M, Klein-Panneton K, Awan AA, Marques M. Gambaro K, et al. Adv Ther. 2026 Mar 10. doi: 10.1007/s12325-026-03545-z. Online ahead of print. Adv Ther. 2026. PMID: 41806276
INTRODUCTION: The treatment landscape for human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) in Canada is rapidly evolving. This retrospective cohort study described real-world historical treatment patterns and clinical outcomes …
INTRODUCTION: The treatment landscape for human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer ( …
Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
GBD 2023 Breast Cancer Collaborators. GBD 2023 Breast Cancer Collaborators. Lancet Oncol. 2026 Mar;27(3):302-326. doi: 10.1016/S1470-2045(25)00730-2. Lancet Oncol. 2026. PMID: 41785894
BACKGROUND: Breast cancer is a leading cause of mortality and morbidity among females worldwide. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, we provided an updated comprehensive assessment of the epidemiological trends, dis …
BACKGROUND: Breast cancer is a leading cause of mortality and morbidity among females worldwide. As part of the Global Burden …
Dermatologic Mimickers of Paget's Disease of the Breast: A Systematic Review.
Volfson E, Moshkovich M, Yakubov R, Dalson J, Kirshen C. Volfson E, et al. J Cutan Med Surg. 2026 Mar-Apr;30(2):125-131. doi: 10.1177/12034754251364870. Epub 2025 Aug 14. J Cutan Med Surg. 2026. PMID: 40814164 Free PMC article.
Mammary Paget disease (MPD) is a rare form of breast cancer that accounts for just 1% to 4% of all cases and is often associated with underlying malignancies such as ductal carcinoma in situ and invasive ductal carcinoma. ...
Mammary Paget disease (MPD) is a rare form of breast cancer that accounts for just 1% to 4% of all cases and is often associat …
ILC2s in cancer: good, bad, or stay tuned?
Asif S, Kinzel M, Vanderhyden B, Jacquelot N, Ardolino M. Asif S, et al. Trends Mol Med. 2026 Mar;32(3):208-210. doi: 10.1016/j.molmed.2025.06.010. Epub 2025 Jul 11. Trends Mol Med. 2026. PMID: 40651913 Review.
254 results